Dr. Bansal uses statistical methods for comparative effectiveness and outcomes research, as well as for the development and evaluation of biomarkers using censored survival data.
Dr. Basu’s research interests include methods and applications for studying observed and unobserved heterogeneity in clinical and economic outcomes.
Dr. Carlson’s research focuses primarily on the intersection of genomics and emerging technologies in the field of personalized medicine, uncertainty in decision-making processes in real-world settings, and improvement of health and health care economic and policy options.
Dr. Goulart is a medical oncologist who specializes in caring for patients with lung cancer and head and neck cancers. His research focuses on the economics of cancer therapies, outcomes, quality of life and health care resources for lung, head and neck cancers.
Dr. Issaka is a gastroenterologist who specializes in the medical and endoscopic management of digestive diseases, including cancer-related complications that affect the gastrointestinal system. Her research focuses on understanding patient barriers to and facilitators of colorectal cancer screening; determining the factors that influence colonoscopy completion following abnormal stool-based screening tests; and identifying gaps in care to implement interventions that improve the quality of cancer control and prevention, particularly in minority populations.
Dr. Kim is a senior fellow in pulmonary and critical care medicine who sees patients with lung diseases and suspected lung cancer at Seattle Cancer Care Alliance. His primary research focus is on the cost of lung cancer diagnosis.
Dr. Lee’s research focuses on new imaging-based cancer screening technologies and appropriate use of advanced imaging in the cancer care continuum. His expertise includes cost-effectiveness analysis and technology assessment.
Dr. Lee’s research focuses on integrating information about patient risk factors, cancer biology and emerging technologies to develop more personalized breast cancer screening and surveillance regimens and to improve population-level outcomes.
Dr. Lyman is a medical oncologist who is internationally recognized for his research on comparative effectiveness, health services and outcomes. He works with care providers, insurance companies, patient advocates, drug companies and other researchers to untangle the financial burden that cancer patients face as they undergo treatment.
Dr. McDermott’s interests include health economics and comparative effectiveness research, with a focus on cancer, end-of-life care and geriatrics.
Dr. Panattoni's research interests include health information technology, economic evaluation, cost methodology and health economics.
Dr. Ramsey is a physician, cancer researcher and health economist. His research interests include cancer outcomes, health care delivery, and economic evaluations of new and existing cancer screening and treatment technologies.
Dr. Roth is a comparative effectiveness researcher with a background in health economics, epidemiology and health services management. His research interests include application of regression modeling, meta-analysis and decision modeling to evaluate chronic disease health outcomes.
Dr. Shah is a behavioral scientist and pharmacist who integrates these two disciplines to study and improve clinical practice and health policy in cancer care delivery. His current research focuses on how pharmacies can serve as health care settings that provide cancer prevention and care services in the community, including HPV vaccinations and colorectal cancer screenings.
Dr. Shankaran is a medical oncologist focusing on esophagus and stomach cancers. Her research interests include measuring the impact of cancer diagnosis and treatment on patients’ and caregivers’ finances and developing strategies to lessen this impact.
Dr. Steuten's research includes health economic analysis and technology assessment with the aim to accelerate patient access to high value health care services and treatments.
Dr. Sullivan’s research interests include technology assessment, medical decision-making and economic evaluation of health care technologies, particularly in the areas of respiratory disorders, cancer and HCV.